SUMMARY Flow cytometry was performed on paraffin embedded tissue from 1 5 cases of Hodgkin's disease. Thirteen (11%) tumours were aneuploid with no significant difference between the histological subgroups. The median proliferative index was 14%, and the highest values were found in the NS2 (16.4%) and lymphocyte depleted (16-0%) subgroups. The difference in proliferative index approached significance when the NS2 subgroup was compared with the NSl subgroup (p < O1 1) and when the lymphocyte depleted and NS2 subgroups combined were compared with the mixed cellularity, lymphocyte predominance, and NSl subgroups combined (p < 0-07).
It is now generally accepted that the Reed-Stemnberg cell and its mononuclear variant represent the malignant cells of Hodgkin's disease. Proliferative activity in these cells has been shown by the nodules"'3and the large series analysed by the British National Lymphoma Investigation (BNLI) confirmed the significantly poorer survival of cases with lymphocyte depleted nodules.'"'6 Several studies of non-Hodgkin's lymphoma have used flow cytometry to assess the DNA content of tumours. These have shown a higher incidence of DNA aneuploidy and increased numbers of cells in Sphase in high grade compared with low grade tumour.'718 The presence of DNA aneuploidy did not seem to have prognostic importance,'9 20 although aneuploid tumours showed a higher remission rate in response to treatment than diploid tumours.2' High numbers of cells in S-phase in non-Hodgkin's lymphoma have also been correlated with decreased survival in some studies,'92022 although this was not confirmed in another study in which patients were followed up for 20 years.2' It has also been reported that high values of S-phase cells identify patients with low grade non-Hodgkin's lymphoma who are at risk of transforming to high grade malignancy. 23 As comparable studies in Hodgkin's disease might yield valuable information, we applied flow cytometry to a large series ofHodgkin's disease cases to assess the significance of differences in ploidy and proliferative index in different histological subgroups, especially in relation to The highest proportions of DNA aneuploid tumours were seen in the mixed cellularity (22.7%) and NS2 (10-5%) subgroups, but significant differences in numbers of DNA aneuploid tumours between the histological subgroups were not observed. The DNA index of the DNA aneuploid tumours varied between 1-2-1-82 (median 1 55).
The highest proliferative indices were found in the NS2 (median 16 4%) and lymphocyte depleted (median 16 0%) subgroups. The differences in proliferative index approached significance when the NS2 subgroup was compared with the NSl subgroup (p < 011) and when the lymphocyte depleted and NS2 subgroups were combined and compared with the combined mixed cellularity, lymphocyte predominance, and NSI subgroups (p < 0-07).
SURVIVAL STUDIES
The median follow up of patients was 39 months (range 2 to 110 months). At the time survival data were calculated, 79 patients were alive and 29 had died.
Of the 108 patients for whom survival data were available, ninety six patients had diploid tumours and 12 had DNA aneuploid tumours. The survival of patients with DNA aneuploid tumours was improved when compared with those with diploid tumours and this approached significance (p < 0 1) (fig 2) . Ofthe 96 patients with diploid tumours, 56 had a proliferative index;of less than 15% and 40 had a proliferative index equal to or greater than 15%. There was a trend towards better survival for cases with a proliferative index below 15%, compared with higher proliferative indices, but this did not reach significance (p < 0 5) (fig 3) . It must be assumed that the proliferative index of Hodgkin's disease tissue reflects the rate of proliferation of both the reactive and neoplastic (ReedSternberg and mononuclear Hodgkin's disease) cells. Although the median proliferative index was highest in the subgroups with least favourable histology, this was not significant, in contrast to the findings in high grade non-Hodgkin's lymphoma. There was a trend towards better survival, however, in the subgroups with a proliferative index below 15%, as was found in low grade non-Hodgkin's lymphoma.2'
From the results ofthis study, we conclude that flow cytometry is unlikely to yield much useful information in determining the prognosis of different histological subtypes of Hodgkin's disease, and that clinical and morphological factors still remain the mainstay of assessment and prognostic indication. Dual parameter flow cytometry of fresh Hodgkin's disease tissue labelled with putative markers of Reed-Stemnberg and mononuclear Hodgkin's disease cells (such as the K,-1 monoclonal antibody) and counterstained for DNA content, however, will permit more sensitive assessment of the presence of aneuploidy and the degree of cell proliferation in these tumours.
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